NCT04856358View on ClinicalTrials.gov

A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

November 8, 2021

Study Completion Date

November 8, 2021

Conditions
Healthy
Interventions
DRUG

GLPG3121

GLPG3121 modified-release tablet

DRUG

Placebo

Matching placebo

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04856358 - A Study to Evaluate How Well Single and Multiple Doses of GLPG3121-modified Release Formulation Are Tolerated in Healthy, Adult Subjects | Biotech Hunter | Biotech Hunter